STATUS EPILEPTICUS MARKET ANALYSIS

Status epilepticus is defined as a condition involving occurrence of a seizure lasting for more than five minutes or experiencing more than one seizure within five minutes without recovering to a normal level of consciousness between episodes. It is characterised by seizures involving abnormal electrical activity in the brain, which can affect both the body and mind. This is a medical emergency, which has the potential to cause irreversible brain damage or death. The most common signs of status epileptics include abnormal sodium or blood sugar levels, brain infections, high fever, and head traumas. Blood sugar imbalances, strokes, and excessive alcohol use can contribute to epileptic seizures. Convulsive and non-convulsive are the two types of status epilepticus. Convulsive status epilepticus occurs when a person suffers a series of tonic-clonic (stiffening and jerking) seizures. For convulsive status epilepticus immediate care in a hospital is necessary as it is associated with loss of consciousness. Non-convulsive status epilepticus occurs when a person experiences a prolonged seizure.

Status epilepticus (SE) is a medical emergency that has a high morbidity and death rate as it is a life-threatening disease. Depending on the underlying cause, complications of status epilepticus can range from no complications to death. To avoid a refractory condition, it is important to early diagnose status epilepticus and begin treatment therapies as soon as feasible. The longer a seizure lasts, the less probable it is to end spontaneously without medicine.

Global Status Epilepticus Market – Dynamics

Emerging potential drugs in pipeline is anticipated to drive the global status epilepticus market during the forecast period. For instance, in October 2020, Marinus Pharmaceuticals a company that develops medicines for uncommon epileptic diseases, started randomized clinical trial for drug Ganaxolone. This study evaluated the effectiveness and safety of IV ganaxolone, to treat patients with status epilepticus. Marinus Pharmaceuticals is about to begin patient enrollment in the drug ganaxolone Phase III RAISE research study.

Increasing incidence of epilepsy in men is projected to boost the global status epilepticus market during the forecast period. For instance, in March 2020, according to The Epidemiology of Epilepsy, men have a higher incidence and prevalence of epilepsy than women. The disparity might be explained by the differing prevalence of the most prevalent risk factors, as well as the condition's concealment in women for sociocultural reasons.

High prevalence of epilepsy and increasing incidence of neurological disorder are expected to increase the demand for status epilepticus treatment, which is anticipated to drive the market growth during the forecast period. For instance, in June 2019, according to the World Health Organization (WHO), status epilepticus is a chronic, noncommunicable central nervous system disease that affects more than 50 million individuals worldwide. Furthermore, seizure recurrence is caused by abnormal brain activity. These seizures result in loss of balder function and other effects, which is estimated to drive the growth of the global status epilepticus market.

Global Status Epilepticus Market – Regional Insights

North America is expected to dominate the global status epilepticus market over the forecast period, owing to increasing funding initiatives and research & development activities in the U.S. For instance, in March 2021, American Epilepsy Society granted fund for prolonged epilepsy up to US$ 50,000 and are intended to support the establishment of national or worldwide multicenter research initiatives. Each award will offer funding for organisational planning sessions, infrastructure development, and/or pilot studies, allowing the research programme to compete for future investment.

Increasing approvals for status epilepticus treatment is expected to propel the market growth during the forecast period. For instance, in April 2018, the U.S. Food and Drug Administration (FDA) granted ZENEO (Midazolam) orphan drug designation to Crossject's treatment for status epilepticus (epileptic seizure lasting longer than five minutes). ZENEO is a pre-filled, single use device that can reportedly deliver a medical formulation through the skin in only 50 milliseconds. The injection parameters of the device may be tailored to the dose, injection route of the medication formulation, and viscosity. Furthermore, according to Crossject, ZENEO Midazolam allows for the fast treatment of epileptic seizures, with an average effect time of 1.2 minutes.

Global Status Epilepticus Market – Taxonomy

By Type:

• Conclusive Epilepticus
• Non Conclusive Epilepticus

By Drug:

• Ganaxolone
• Diazepam
• Fosphenytoin 
• Valproate 
• Phenobarbital
• Phenytoin
• Others

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa

Global Status Epilepticus Market – Competitive landscape

Key players involved in the global status epilepticus market include SAGE Therapeutics, Marinus Pharmaceuticals, H.Lundbeck, CURx Pharmaceuticals, Sunovion Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Sanofi S.A., GlaxoSmithKline plc, and Johnson & Johnson.